Novel Toxicology Screening Assay for Drug Molecules


Project ID:  D2014-28

Novelty: A microplate-based assay approach to evaluate mammalian cell toxicity of drug molecules during early stage drug development.

Background: Realizing potential toxicity issues in early drug development can assist in the design of compounds at an early stage of development and reduce in vivo toxicity issues. However, there is an unmet demand of a convenient and affordable screening platform, especially during early stages of identification of novel classes of compounds, where a large number of analogues must be evaluated and their specific mechanisms of toxicity are unknown. Novel in vitro assays for toxicity tests against a variety of representative mammalian cell types can provide a readily obtainable and cost-effective means of establishing toxicity, structure-activity relationships (SAR), designing improved analogues, and selecting promising agents for more rigorous testing.

Assay Description: Researchers at the University of Toledo have established a microplate-based, dual-assay approach using a single reagent to evaluate mammalian cell toxicity during early stage development1. Toxicity assays were performed with a panel of mammalian cells derived from representative susceptible tissues, cardiac, renal, liver, and neural. Additional mammalian cell lines can be added as required. Application of this screening approach to early drug development demonstrates the ability of these assays to identify potential toxicity issues.

Applications: To identify potential toxicity issues early in drug development.


Sarver JG, Trendel JA, Bearss NR, Wang L, Luniwal A, Erhardt PW, Viola RE. Early stage efficacy and toxicology screening for antibiotics and enzyme inhibitors. J Biomol Screen. 2012 Jun; 17(5):673-82. [Link]
Patent Information:
For Information, Contact:
Stephen Snider
AVP Tech Transfer
The University of Toledo
419 530 6225
Jill Trendel
Jeffrey Sarver
Nicole Bearss